TSO3 Inc. (TSE:TOS) – Investment analysts at Desjardins reduced their FY2019 earnings estimates for TSO3 in a research report issued to clients and investors on Thursday, August 9th. Desjardins analyst F. Tremblay now forecasts that the company will earn ($0.13) per share for the year, down from their previous forecast of ($0.10).

Several other brokerages also recently commented on TOS. Royal Bank of Canada cut their price objective on shares of TSO3 from C$1.75 to C$1.50 and set a “sector perform” rating on the stock in a research report on Thursday, May 3rd. National Bank Financial cut their price objective on shares of TSO3 from C$1.50 to C$1.25 and set a “sector perform” rating on the stock in a research report on Thursday, August 2nd. Finally, Canaccord Genuity cut their price objective on shares of TSO3 from C$2.40 to C$2.00 in a research report on Thursday, May 10th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of C$1.60.

Shares of TOS stock opened at C$0.67 on Monday. TSO3 has a one year low of C$0.56 and a one year high of C$2.90.

In related news, Director Linda Rosenstock bought 43,000 shares of the stock in a transaction on Thursday, August 9th. The shares were acquired at an average price of C$0.67 per share, for a total transaction of C$28,810.00.

About TSO3

TSO3 Inc engages in the research, development, production, maintenance, sale, and licensing of sterilization processes, related consumable supplies, and accessories for heat and moisture sensitive medical devices worldwide. Its principal product is the STERIZONE VP4 sterilizer, a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide and ozone that is marketed in Canada and the United States.

Read More: NASDAQ

Earnings History and Estimates for TSO3 (TSE:TOS)

Receive News & Ratings for TSO3 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TSO3 and related companies with MarketBeat.com's FREE daily email newsletter.